Whitepaper: Impact of the Claristep® Filtration System on recovery and adsorption of various therapeutic proteins at low sample volumes
Posted: 10 July 2019 | Sartorius | No comments yet
Comparison of the Sartorius Claristep Filtration System with standard sample preparation using syringe filters.
We tested the novel filter device Claristep® for the preparation of protein samples containing one of four different target molecules: an anti-malaria vaccine candidate, aviscuminum, interferon alfa-2B or monoclonal antibody (mAb) P2G12. In comparison to the standard protocols for sample preparation prior to analysis by either reversed-phase or SEC HPLC, the Claristep® filter did not exhibit a significant difference in protein concentration if the target molecules were present with at least 1.0g L-1. A significantly reduced product concentration was observed in the Claristep® filtered samples compared to the standard protocol for mAb P2G12 if the concentrations were lower. The protein adsorption to the filter material was well described by a Langmuir adsorption isotherm. In addition, the Claristep® filters facilitated a rapid sample preparation with minimal volume losses.
Related content from this organisation
- Quality from the start: designing a scalable AAV production platform
- European Pharmaceutical Review Issue 4 2024
- Application note: Equivalency of PCR-based rapid sterility testing and the compendial culture method
- Product hub: Choosing the right tool for method screening and process optimisation
- Microbial fermentation tech market to exceed $56.9b by 2033
